A study that will involve acquiring input on healthcare workers’ experience with medical marijuana and advice on the same was recently announced. The study, which will involve experts from the University of Massachusetts’ Dartmouth Charlton College of Business, Medicinal Genomics and the Cannabis Center of Excellence Inc. (“CCOE”) will focus on health-care workers in both Canada and the United States.
The study will gather information on the experiences of health-care providers with medical marijuana in their practices and the interest they may have in future clinical education associated with medical marijuana.
Cannabis Center of Excellence Inc. president Dr. Marion McNabb highlighted that approaches to incorporate medical marijuana use, along with knowledge of the risks and benefits of medical marijuana and the endocannabinoid system’s basics weren’t part of the regular curriculum for the majority of the health professionals. This includes those in emergency medicine, addiction and recovery, public health, dental, nursing and medical.
As more evidence on the effectiveness of marijuana is unearthed, the study’s objective is to hear from health-care providers on how the use of marijuana can be incorporated into their practices. In addition to this, the study will also focus on what health-care providers want to know about medical marijuana and what they do know.
A study that was published in 2019 discovered that more than 58% of health-care providers were of the opinion that medical marijuana was a legitimate medical therapy. The authors of the study noted that for provider concerns to be addressed, accurate information on the potential for drug interactions needed to be spread.
A separate study noted that standardized education would make sure that health-care providers were prepared to promote the responsible use of marijuana if it had been indicated for medically appropriate conditions and symptoms.
Despite the advances made though, more is still required. Earlier in April, a study conducted in Israel found that Israeli medical students felt unprepared despite the fact that they were more supportive of the use of medical marijuana to manage pain, in comparison with their counterparts in Thailand.
The CCOE also revealed that the study, which is backed by the Super Critical Labs, has been approved for human research by the Dartmouth Institutional Review Board. It also noted that the anonymous survey, which would be available from May 2021 to May 2022, would take roughly 12 minutes for health-care providers to complete.
McNabb, who is the chief investigator, will be joined by 15 other researchers, including veterans, clinicians and other scientists. The body expects that initial study results will be available by October 2021.
As a growing amount of more marijuana research is done by independent entities, the products made by sector players such as Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are likely to gain more acceptance from the medical community since the products will be better understood by that segment.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://cnw.fm/PULL
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.